The Oil & Gas Journal, first published in 1902, is the world's most widely read petroleum industry publication. OGJ delivers international oil and gas industry news; analysis of issues and events; practical technology for design, operation, and maintenance of oil and gas operations; and important statistics on energy markets and industry activity.

OGJ is edited to meet the needs of engineers, geoscientists, managers, and executives throughout the oil and gas industry. It is part of Endeavor Business Media, Nashville, Tenn., which also publishes Offshore Magazine.

Endeavor Business Media’s Petroleum Group also produces targeted e-Newsletters; hosts global conferences and exhibitions, seminars, and forums; and publishes directories, technical books, print and electronic databases, surveys, and maps.

Additional Information

Website & Technical Help

For help with subscription purchases or refunds, or trouble logging into the paid subscription content on www.ogj.com, please contact Customer Service at [email protected] or call 1-847-559-7598.

For more customer service information, please click here.

Jade Biosciences to Participate in Upcoming Investor Conferences

VANCOUVER, British Columbia and SAN FRANCISCO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Jade Biosciences (“Jade”), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that the company will participate in two upcoming investor conferences in November 2024.

Tom Frohlich, Chief Executive Officer, will deliver a company presentation at the Stifel 2024 Healthcare Conference on November 18, 2024 at 4:45 p.m. ET, and at the 2024 Jefferies London Healthcare Conference on November 20, 2024 at 12:00 p.m. GMT (U.K.).

Members of the Jade management team will also host investor meetings during the conferences.

Investors and the general public are invited to listen to both sessions at their respective times by visiting the Investors and Media page on JadeBiosciences.com. An archived edition of each session will be available following its conclusion for 90 days.

About Jade Biosciences

Jade Biosciences is focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Its lead asset, JADE-001, will target the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for immunoglobulin A (IgA) nephropathy, with Investigational New Drug Application-enabling studies underway and initiation of a first-in-human trial expected in the second half of 2025. Jade’s pipeline also includes two undisclosed optimized antibody discovery programs, JADE-002 and JADE-003, currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. For more information, visit JadeBiosciences.com and follow the Company on LinkedIn.

Jade Biosciences Contact

Media:
Media@JadeBiosciences.com

Investors:
IR@JadeBiosciences.com


Primary Logo

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.